Stay updated with breaking news from Proprietary Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Combination with Marquee Raine Acquisition Corp. Values Enjoy at an Approximate Enterprise Value of $1.2 Billion, Expected to Provide More Than $450 Million of Growth Capital for Enjoy to Achieve
Enjoy Technology to Become a Public Company, Accelerating its Strategy to Reinvent "Commerce at Home" News provided by Share this article Share this article Combination with Marquee Raine Acquisition Corp. Values Enjoy at an Approximate Enterprise Value of $1.2 Billion, Expected to Provide More Than $450 Million of Growth Capital for Enjoy to Achieve Approximately $1 Billion in Revenue by 2025 Underpinned by Proprietary Technology, Exclusive Relationships with Leading Consumer Brands, and a Compelling Margin Profile, Enjoy Has First-Mover Advantage in Large and Growing Total Addressable Mar...
Palantir Technologies Inc (NYSE: PLTR) and BlackBerry Ltd (NYSE: BB) have each snagged a slew of partnerships over the past year, disrupting the technology space and putting them in the spotlight as true growth companies. What Happened: Although both companies have been in business for years -- Palantir was founded in 2003, BlackBerry in 1984 — their proprietary technology has become increasingly sought after by numerous companies across many major sectors. The companies have a lot in common too. Each company's platforms have disrupted the technology space by changing the course of...
Impel NeuroPharma, a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the appointments of Leonard S. Paolillo as chief commercial officer and Gerald F. Penn as vice president, market access and trade. These key management additions further the build out of the commercial infrastructure of the organization as it prepares for the potential launch of TRUDHESA™ for the acute treatment of migraine headaches with or without ...